Our Company
Celtaxsys, Inc. of Atlanta is a biopharmaceutical company focused on development and commercialization of innovative pharmaceutical products to treat unmet medical needs by controlling immune cell traffic.The Company's core technology is based on the process of chemorepulsion, the ability of a chemical stimulus to cause a cell to move away from the source of the stimulus. Through extensive screening efforts, Celtaxsys has identified a number of potent chemorepellant compounds that redirect migration of important immune cells called neutrophils. As part of the innate immune system, neutrophils are typically the first-responders and gatekeepers during an inflammatory event and, as such, provide an early point of intervention to head-off unwanted immune escalation and tissue damage. Our mission is to identify and treat patient populations, small and large, suffering from diseases driven by misdirected neutrophil response and poorly addressed by other therapies. Celtaxsys is actively engaging physician, patient, research and drug development communities to form productive partnerships that result in real solutions for real patient needs.
Pipeline Highlights
Celtaxsys has a rich and diversified pipeline of chemorepellant compounds in various phases of preclinical development. Our library of chemorepellants includes small molecule compounds, peptides and proteins, some of which are existing drugs approved for non-inflammatory indications (repurposed drugs) and others are new chemical entities (NCEs). The spectrum of activities and properties encompassed in the Celtaxsys chemorepellant library provides a ready source for discovery and development opportunities.
Our initial product candidates are small molecule chemorepellants that address a major limitation of injected drugs, which are the most prevalent and effective drugs for some of the largest pharmaceutical markets in the world including Multiple Sclerosis, Rheumatoid Arthritis, Hepatitis C and HIV. Patient tolerance is a significant limitation to effective adherence to treatment with these drugs. Without consistent application of proper treatment for these dire diseases, the patient progresses more rapidly toward incapacity. Celtaxsys’ drug candidates make these important injected medicines more tolerable by reducing the inflammation associated with the injection (an effect called an injection site reaction). Because injection site reactions are often painful and can even be disfiguring, they result in a significant number of patients stopping much-needed therapy.
Celtaxsys is tapping its neutrophil chemorepellant library to build a pipeline by targeting diseases in two classes: diseases with low incidence but high need (niche indications) including neutrophil-driven forms of Dermatosis, Vasculitis and Panniculitis; and more prevalent diseases (major disease markets) where neutrophil involvement is emerging as a key disease driver including Uveitis, Inflammatory Bowel Disease (IBD), Ulcerative Colitis, Psoriasis and Acne.